Oesophageal Cancer
FEATURES
avatar
0 clinical trials
avatar
7 cell line models
avatar
5 approved drugs
IMAGE
Oesophageal Cancer
Molecular Synopsis
OVERVIEW
Drugs and clinical candidates

5 drugs have received FDA approval for Oesophageal Cancer:

  • Docetaxel
  • Pembrolizumab
  • Ramucirumab
  • Trastuzumab
  • Trifluridine

No drugs have a clinical trial registered for Oesophageal Cancer.

47 compounds have been tested in Oesophageal Cancer (44 <= 500nM potency).

Sources: cancer.gov, clinicaltrials.gov, ChEMBL.

Clinical trials
There are 0 clinical trials for Oesophageal Cancer, none of which have one or more drug interventions, none with no drug intervention.
Cell line models

There are 7 Cell Line Models for Oesophageal Cancer.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Oesophageal Cancer:
    The following terms have been mapped from cancer.gov to Oesophageal Cancer:
    • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that has metastasized. It is used in adults who have already received at least two treatments with a fluoropyrimidine and platinum chemotherapy and either a taxane or irinotecan and, in some cases, HER2/neu-targeted therapy
    • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that is advanced. It is used in patients whose disease has not been treated with chemotherapy
    • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that is advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease has gotten worse after treatment with a fluoropyrimidine or platinum chemotherapy. It is used alone or with paclitaxel
    • Gastric (stomach) cancer or gastroesophageal junction cancer that is recurrent and either locally advanced or metastatic. It is used in patients whose cancer has the PD-L1 protein and whose disease got worse during or after two or more types of treatment including a fluoropyrimidine and platinum chemotherapy and, in some cases, HER2/neu targeted therapy.????
    • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that has metastasized. It is used in patients whose disease is HER2+. This use is approved for the Herceptin and Ogivri brands of trastuzumab